Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 200, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112426
Keywords
Epigenetic readers; KAc; BRD4; Bivalent inhibitors; PTOTACs; Dual target inhibitors
Categories
Ask authors/readers for more resources
As epigenetic readers of the histone code, BRD4 is the most extensively and thoroughly studied member of BET family, which plays a critical role in many human diseases including cancer, inflammation, HIV infections, CNS disorders, and cardiovascular diseases and has been proved to be a promising therapeutic target for these diseases. To date, many small-molecule BRD4 inhibitors have been discovered, and some of them are in clinical trials for the treatment of different diseases. Due to the lack of selectivity of these small molecules for BRD4 BD1, BRD4 BD2 and/or other BET proteins, they exert some toxic side effects, including dizziness, nausea, and vomit. Now, novel strategies are urgent needed to improve the selectivity and reduce the side effects of current BRD4 inhibitors. Herein, in this article, we made a summary of the recent development of novel strategies targeting BRD4. Opportunities for these strategies to achieve selective and efficacious BRD4 inhibitors for treating human diseases are also highlighted. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available